Chardan Capital Issues Positive Forecast for Palvella Therapeutics (NASDAQ:PVLA) Stock Price

Palvella Therapeutics (NASDAQ:PVLA) had its price objective upped by Chardan Capital from $174.00 to $210.00 in a research note released on Tuesday, Marketbeat.com reports. The brokerage currently has a buy rating on the stock.

A number of other research firms also recently weighed in on PVLA. BTIG Research restated a “buy” rating and set a $192.00 target price on shares of Palvella Therapeutics in a research report on Thursday, January 29th. UBS Group reiterated a “buy” rating and issued a $143.00 price objective on shares of Palvella Therapeutics in a research report on Monday, December 15th. Craig Hallum started coverage on shares of Palvella Therapeutics in a research report on Thursday, December 4th. They set a “buy” rating and a $175.00 target price on the stock. Cantor Fitzgerald raised their target price on shares of Palvella Therapeutics from $120.00 to $200.00 and gave the company an “overweight” rating in a research note on Thursday, November 6th. Finally, HC Wainwright lifted their price target on shares of Palvella Therapeutics from $200.00 to $255.00 and gave the stock a “buy” rating in a research report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $172.19.

Palvella Therapeutics Price Performance

PVLA stock opened at $120.41 on Tuesday. The company has a 50 day moving average price of $92.05 and a 200 day moving average price of $78.51. Palvella Therapeutics has a fifty-two week low of $18.23 and a fifty-two week high of $127.69. The stock has a market capitalization of $1.43 billion, a PE ratio of -45.78 and a beta of -0.16.

Insider Buying and Selling at Palvella Therapeutics

In related news, COO Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $97.63, for a total transaction of $420,004.26. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 20.50% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Palvella Therapeutics

A number of hedge funds have recently modified their holdings of the business. Archer Investment Corp acquired a new stake in shares of Palvella Therapeutics in the third quarter valued at approximately $28,000. Group One Trading LLC increased its stake in Palvella Therapeutics by 151.5% in the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock valued at $35,000 after buying an additional 200 shares during the last quarter. Russell Investments Group Ltd. bought a new stake in Palvella Therapeutics during the 3rd quarter worth about $36,000. Police & Firemen s Retirement System of New Jersey bought a new stake in Palvella Therapeutics during the 2nd quarter worth about $37,000. Finally, JPMorgan Chase & Co. boosted its stake in shares of Palvella Therapeutics by 108,066.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock worth $73,000 after buying an additional 3,242 shares during the last quarter. Institutional investors and hedge funds own 40.11% of the company’s stock.

Key Palvella Therapeutics News

Here are the key news stories impacting Palvella Therapeutics this week:

• Positive Sentiment: Phase 3 SELVA topline: the trial met its primary endpoint (mLM-IGA, mean change +2.13; p<0.001), hit key secondary endpoints, showed 95% of evaluable patients ≥6 improved and 86% were “Much/Very Much Improved,” reported favorable tolerability, and Palvella plans an NDA submission in H2 2026 — a path to the first potential FDA-approved therapy for microcystic LMs. GlobeNewswire: Phase 3 SELVA topline Yahoo Finance: Positive Topline Results QuiverQuant: Phase 3 summary
• Positive Sentiment: Analyst upgrade/target lift: Chardan Capital raised its price target (now $210) and maintains a Buy — adds institutional validation and raises the stock’s upside expectations. The Fly: Price target raised
• Neutral Sentiment: Conference call/webcast: management hosted a call to discuss SELVA topline results — listen for color on safety, patient-reported outcomes, extension enrollment and NDA timing/strategy. Business Insider: conference call GlobeNewswire: conference call notice
• Neutral Sentiment: Technical/market commentary: coverage noting the stock’s breakout past the 50-day moving average and pre-market gap higher — these technicals amplify intraday momentum but aren’t new fundamentals. MSN: 50-day breakout MSN: pre-market surge
• Negative Sentiment: Proposed public offering announced: the company filed for a proposed offering (timing/size unspecified), which could be dilutive — investors will watch terms closely as proceeds could fund NDA/commercial launch but may pressure the share count. Business Insider: Proposed public offering

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.